Pulse Biosciences, Inc.

Merck & Co. Inc. 's R&D head in China, Zhenqin Li , is leaving to pursue opportunities outside the company effective Feb. 28, announced the US firm, which operates as Merck Sharp & Dohme Ltd. outsi

Device Transactions The device industry pulled in $1.5 billion in financing during the second quarter of 2016, a 15% drop from Q1's $1.8 billion. Once again, debt offerings played a big role, represen

Pulse Biosciences Inc. expects to begin a pilot study of its PulseTx nano-pulse system for immunoncology applications within a year, building on preclinical research showing that very short pulses

2016 proved to be a slow starter for medtech IPOs with only one company pulling off an initial public offering in the first quarter. However, the public markets looked more amenable in the second quar